Morgan Stanley raised the firm’s price target on Pfizer to $29 from $28 and keeps an Equal Weight rating on the shares after the company posted a Q1 beat, reiterated 2024 revenue guidance and raised 2024 EPS guidance. Management commentary on the call “suggested cautious optimism on the outlook for the remainder of the year,” though the firm maintains its Equal Weight rating given its focus on new product cycles and pipeline progress to address upcoming patent cliffs, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- PFE Earnings: Pfizer Rises After Smashing Q1 Estimates
- Options Volatility and Implied Earnings Moves Today, May 01, 2024
- Pfizer raises FY24 adjusted EPS view to $2.15-$2.35 from $2.05-$2.25
- Pfizer reports Q1 adjusted EPS 82c, consensus 52c
- Pfizer developing online platform to sell drugs directly to consumer, FT says